Testing effectiveness (Phase 2)Looking for participantsNCT05925504
What this trial is testing
The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes
Who this might be right for
Lower Risk MDS Per IPSS-R
Institute of Hematology & Blood Diseases Hospital, China 36